MX2024001644A - Anticuerpos contra el receptor alfa de la interleucina-4 humana. - Google Patents

Anticuerpos contra el receptor alfa de la interleucina-4 humana.

Info

Publication number
MX2024001644A
MX2024001644A MX2024001644A MX2024001644A MX2024001644A MX 2024001644 A MX2024001644 A MX 2024001644A MX 2024001644 A MX2024001644 A MX 2024001644A MX 2024001644 A MX2024001644 A MX 2024001644A MX 2024001644 A MX2024001644 A MX 2024001644A
Authority
MX
Mexico
Prior art keywords
receptor alpha
human interleukin
alpha antibodies
antibodies
human
Prior art date
Application number
MX2024001644A
Other languages
English (en)
Inventor
Donmienne Doen Mun Leung
Yiqing Feng
Shane Krummen Atwell
Diana Isabel Ruiz
Songqing Na
Maya Rachel Karta
Laura Anne Pelletier
David John Stokell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2024001644A publication Critical patent/MX2024001644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se relaciona con anticuerpos que se unen específicamente a IL-4Ra humano, composiciones que comprenden tales anticuerpos IL-4Ra y métodos para usar tales anticuerpos IL-4Ra.
MX2024001644A 2021-08-05 2022-08-05 Anticuerpos contra el receptor alfa de la interleucina-4 humana. MX2024001644A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229836P 2021-08-05 2021-08-05
US202263348388P 2022-06-02 2022-06-02
PCT/US2022/074575 WO2023015278A1 (en) 2021-08-05 2022-08-05 Human interleukin-4 receptor alpha antibodies

Publications (1)

Publication Number Publication Date
MX2024001644A true MX2024001644A (es) 2024-02-27

Family

ID=83193316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001644A MX2024001644A (es) 2021-08-05 2022-08-05 Anticuerpos contra el receptor alfa de la interleucina-4 humana.

Country Status (14)

Country Link
US (1) US11891441B2 (es)
EP (1) EP4380979A1 (es)
JP (1) JP2024530467A (es)
KR (1) KR20240039025A (es)
AU (1) AU2022324620A1 (es)
CA (1) CA3227516A1 (es)
CO (1) CO2024001251A2 (es)
CR (1) CR20240046A (es)
DO (1) DOP2024000020A (es)
EC (1) ECSP24009186A (es)
IL (1) IL310419A (es)
MX (1) MX2024001644A (es)
TW (1) TW202328183A (es)
WO (1) WO2023015278A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235738A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company Human interleukin-4 receptor alpha antibody glucocorticoid conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003393A (es) * 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
JP7073487B2 (ja) 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN111518211B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途

Also Published As

Publication number Publication date
KR20240039025A (ko) 2024-03-26
WO2023015278A1 (en) 2023-02-09
IL310419A (en) 2024-03-01
CO2024001251A2 (es) 2024-03-07
DOP2024000020A (es) 2024-03-28
TW202328183A (zh) 2023-07-16
CR20240046A (es) 2024-03-11
ECSP24009186A (es) 2024-03-01
JP2024530467A (ja) 2024-08-21
EP4380979A1 (en) 2024-06-12
US20230064378A1 (en) 2023-03-02
CA3227516A1 (en) 2023-02-09
US11891441B2 (en) 2024-02-06
AU2022324620A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
UA112416C2 (uk) Антитіло до fap і способи його застосування
PH12021550764A1 (en) Trem2 stabilizing antibodies
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
PH12020500667A1 (en) Multispecific antibodies and use thereof
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022010621A (es) Anticuerpos anti-cd19 humano.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2023012325A (es) Anticuerpos anti-tslp modificados.
MX2024001644A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2023006832A (es) Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
MX2024005683A (es) Anticuerpos contra el factor de necrosis tumoral alfa humano.
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2023009434A (es) Anticuerpos contra cd112r y usos de los mismos.
MX2022009130A (es) Anticuerpos anti-e-selectina, composiciones y metodos de uso.
MX2022016494A (es) Anticuerpos anti-il13ra2.